HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 ...

To lessen bruising, do not rub the injection site after each dose. Learn how to store and discard medical supplies safely. Patients who are getting immune globulin for the first time, those who ...

"We are very pleased that patients in Japan with agammaglobulinemia or hypogammaglobulinemia can now access HYQVIA, which represents the first and only subcutaneous immunoglobulin therapy that ...

Vera Therapeutics, Inc. (NASDAQ:VERA) saw its stock soar by 80% following the announcement of encouraging data from its ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

but subcutaneous immunoglobulin bypasses this issue. The CSL-sponsored trial also uses a control injection of the same volume to ensure accuracy, she said. Animal studies from Iwasaki’s lab have ...

HYQVIA combines subcutaneous immunoglobulin (10% ... with manageable side effects such as mild fever and injection site reactions. Takeda's commitment to offering differentiated immunoglobulin ...

Takeda, is focused on creating better health for people and a brighter future for the world, announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of Hyqvia [Immune ...

The treatment, a weekly 30-to-90 second subcutaneous injection, is the first neonatal Fc receptor (FcRn) blocker approved for CIDP. It works by decreasing the recycling of immunoglobulin G (IgG ...

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant ...